OncoMatch/Clinical Trials/NCT06686576
A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer
Is NCT06686576 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including QL1706 and CAPEOX/Capecitabine for colon cancer.
Treatment: QL1706 · CAPEOX/Capecitabine — The goal of this clinical trial is to evaluate the efficacy of neoadjuvant QL1706 in participants with untreated T4N0 or Stage III (resectable), microsatellite instability high/ defective mismatch repair (MSI-H/dMMR) colon cancer
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Colorectal Cancer
Disease stage
Required: Stage IIB, III (AJCC Stage VIII)
Excluded: Stage DISTANT METASTATIC DISEASE
Radiographic assessment showed a resectable stage IIB-III based on AJCC Stage VIII (cT4 or cN+ only). Has distant metastatic disease [excluded].
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: any antitumor therapy
Lab requirements
Blood counts
Adequate organ function as described in the protocol
Kidney function
Adequate organ function as described in the protocol
Liver function
Adequate organ function as described in the protocol
Adequate organ function as described in the protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06686576 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage IIB or III is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages